“Comparative Outcomes of Donor Graft CD34+ Selection and Immune Suppressive Therapy as Graft-Versus-Host Disease Prophylaxis for Patients with Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transpl”, J Clin Oncol, vol. 30, pp. 3194-3201, 2012.,
“Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care In Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome*”, Biol Blood Marrow Transplant, vol. 20, pp. 1566-1572, 2014.,
“Recommendations for Donor Human Leukocyte Antigen Assessment and Matching for Allogeneic Stem Cell Transplantation: Consensus Opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)”, Biol Blood Marrow Transplant, vol. 21, no. 1, pp. 4-7, 2014.